Skip to content

D&A at other companies

Guardant Health logo
Guardant HealthGH
$9.44M-7.8%
Natera, Inc. logo
Natera, Inc.NTRA
$14.52M+57.2%
Immunome logo
ImmunomeIMNM
$603K-1.3%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$3.42M-20.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$723K-12.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$559K+26.1%

Segments

By segment

See full
Reportable Segment$37.22M-1.2%

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s D&A?
GRAIL, Inc. (GRAL) reported D&A of $4.21M in Q1 2026.
How has GRAIL, Inc.'s D&A changed year-over-year?
GRAIL, Inc.'s D&A decreased by 10.3% year-over-year, from $4.7M to $4.21M.
What is the long-term trend for GRAIL, Inc.'s D&A?
Over 2 years (2022 to 2025), GRAIL, Inc.'s D&A has grown at a 4.7% compound annual growth rate (CAGR), from $16.43M to $18.01M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.